Context ends bispecific trial to extend runway deeper into 2027
Context Therapeutics is discontinuing its bispecific antibody trial to conserve cash and extend its runway deeper into 2027.
Context Therapeutics
NASDAQ: CNTX $0.36 USD
Clinical-stage biopharmaceutical company (NASDAQ: CNTX) advancing medicines for solid tumors, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody. In August 2026 the company discontinued its bispecific program to extend its cash runway into 2027.
Company Info
Sector:Oncology / Small Molecule Pharma
Headquarters:Philadelphia, Pennsylvania, USA
Founded:2015
Website:www.contexttherapeutics.com/
Upcoming Milestones & Key Dates
2027
Corporate
Cash runway extended into 2027 after bispecific program discontinued
Clinical Development Pipeline
CTIM-76
Target: CLDN6 x CD3 bispecificRecent News
Leadership Team
Martin Lehr
Co-founder and Chief Executive Officer
Christopher Beck
Senior Vice President of Operations
Michael Girouard
Executive Director, Quality